Amgen, Inc. (NASDAQ:AMGN) Shares Acquired by Westpac Banking Corp
Westpac Banking Corp lifted its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 106,485 shares of the medical research company’s stock after purchasing an additional 3,484 shares during the quarter. Westpac Banking Corp’s holdings in Amgen were worth $19,623,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in Amgen by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock worth $1,720,250,000 after acquiring an additional 482,760 shares during the last quarter. Mackay Shields LLC bought a new stake in Amgen in the 4th quarter worth $59,742,000. Lehman & Derafelo Financial Resources LLC bought a new stake in Amgen in the 4th quarter worth $205,000. Lido Advisors LLC grew its holdings in Amgen by 3.6% in the 4th quarter. Lido Advisors LLC now owns 5,009 shares of the medical research company’s stock worth $975,000 after acquiring an additional 172 shares during the last quarter. Finally, Avalon Advisors LLC grew its holdings in Amgen by 64.9% in the 4th quarter. Avalon Advisors LLC now owns 216,296 shares of the medical research company’s stock worth $42,106,000 after acquiring an additional 85,103 shares during the last quarter. 78.96% of the stock is currently owned by institutional investors and hedge funds.
AMGN has been the topic of a number of recent analyst reports. Credit Suisse Group began coverage on shares of Amgen in a report on Monday, May 20th. They issued an “outperform” rating and a $208.00 price target on the stock. BMO Capital Markets set a $230.00 target price on shares of Amgen and gave the stock a “buy” rating in a research report on Wednesday, July 31st. BidaskClub raised shares of Amgen from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Cowen reaffirmed a “buy” rating and issued a $229.00 target price on shares of Amgen in a research report on Wednesday, May 1st. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Amgen in a research report on Friday. Nine analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Amgen has an average rating of “Buy” and a consensus price target of $211.78.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.58 by $0.39. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The company had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same period last year, the company posted $3.83 EPS. Amgen’s revenue was down 3.1% on a year-over-year basis. As a group, research analysts expect that Amgen, Inc. will post 14.23 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 6th. Shareholders of record on Thursday, August 15th will be paid a dividend of $1.45 per share. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $5.80 dividend on an annualized basis and a yield of 2.83%. Amgen’s dividend payout ratio is currently 40.28%.
In other Amgen news, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total transaction of $77,792.00. Following the completion of the sale, the director now directly owns 16,336 shares in the company, valued at approximately $2,990,141.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $187.58, for a total transaction of $375,160.00. Following the sale, the director now owns 16,336 shares of the company’s stock, valued at $3,064,306.88. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,425 shares of company stock valued at $804,312. 0.25% of the stock is owned by company insiders.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Recommended Story: Why is the conference call important?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.